Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Phaxiam Therapeutics SA (PHXM)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2.9500 0.0000    0.00%
26/04 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  France
ISIN:  FR001400K4B1 
  • Volume: 16,261
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 2.9050 - 2.9500
Phaxiam Therapeutics 2.9500 0.0000 0.00%

PHXM Recent Sentiments

 
This page contains information on users’ sentiments for the Phaxiam Therapeutics SA stock, which are displayed both on charts of different periods of time and on a detailed table.
BearishBullish
Start Date Username Call Open Rate End Date Chg. %
Apr 09, 2024 Gretta Garbo   2.8700 +2.79%
Mar 05, 2024 charles daunis   2.9600 Mar 29, 2024 @ 2.9800 +0.68%
Mar 05, 2024 Martijn Ram   3.0000 Mar 11, 2024 @ 2.9400 -2.00%
Mar 05, 2024 Philippe Benard   3.0000 Mar 29, 2024 @ 2.9800 -0.67%
Feb 22, 2024 JPIERRE ALESSI   2.9400 Feb 26, 2024 @ 2.9800 +1.36%
Feb 15, 2024 Ernesto Pailos   3.2050 Mar 08, 2024 @ 2.9850 -6.86%
Feb 01, 2024 Gretta Garbo   3.7100 Feb 23, 2024 @ 2.8500 -23.18%
Jan 29, 2024 Laurent Desmulliez   3.9700 Feb 23, 2024 @ 2.8500 -28.21%
Dec 07, 2023 Ferreira Mickaël   4.4550 Dec 29, 2023 @ 4.6000 +3.25%
Dec 06, 2023 Ernesto Pailos   4.5800 Dec 29, 2023 @ 4.6000 -0.44%
Dec 06, 2023 Philippe Benard   4.5800 Dec 29, 2023 @ 4.6000 +0.44%
Dec 04, 2023 KEUSSES André   4.5500 Dec 29, 2023 @ 4.6000 +1.10%
Nov 30, 2023 Catherine korady   4.1650 Dec 22, 2023 @ 4.6100 +10.68%
Nov 27, 2023 Alpino Di stella   4.1100 Dec 22, 2023 @ 4.6100 +12.17%
Sep 20, 2023 JB Arnaud   5.1200 Nov 30, 2023 @ 4.1000 -19.92%
Sep 20, 2023 damien miquel   4.9000 Nov 30, 2023 @ 4.1000 -16.33%
Sep 18, 2023 Fabrizio Beatrici   2.6000 Sep 19, 2023 @ 5.4500 +109.62%
Sep 18, 2023 Fabrizio Beatrici   6.0000 Sep 18, 2023 @ 2.6000 +56.67%
Aug 11, 2023 Juan FLORES   50.0000 Nov 30, 2023 @ 4.1000 -91.80%
Aug 10, 2023 Nico Duin   52.8000 Nov 30, 2023 @ 4.1000 -92.23%
Aug 10, 2023 Robert Grena   52.9000 Nov 30, 2023 @ 4.1000 -92.25%
Aug 08, 2023 Kevin Paulus   36.8000 Nov 30, 2023 @ 4.1000 -88.86%
Aug 04, 2023 Vincent Vigneron   37.0000 Nov 30, 2023 @ 4.1000 -88.92%
Aug 04, 2023 Duracel La Pile   37.0000 Nov 30, 2023 @ 4.1000 +88.92%
Aug 01, 2023 Nico Perso   47.0000 Nov 30, 2023 @ 4.1000 +91.28%
Jul 31, 2023 KEUSSES André   49.7000 Nov 30, 2023 @ 4.1000 -91.75%
Jul 31, 2023 Claudio Tonoli   49.5000 Nov 30, 2023 @ 4.1000 -91.72%
Jul 28, 2023 charles daunis   54.7000 Nov 30, 2023 @ 4.1000 -92.50%
Jul 24, 2023 Jérôme Tricot   61.1000 Nov 30, 2023 @ 4.1000 -93.29%
Jul 20, 2023 Bernard Girollet   63.0000 Nov 30, 2023 @ 4.1000 -93.49%
Jul 06, 2023 Pierre PLEYNET   64.9000 Nov 30, 2023 @ 4.1000 +93.68%
Jul 06, 2023 Catherine korady   63.8000 Nov 30, 2023 @ 4.1000 -93.57%
Jul 05, 2023 Philippe Benard   61.1000 Nov 30, 2023 @ 4.1000 -93.29%
Jul 05, 2023 Niels Walker   56.5000 Nov 30, 2023 @ 4.1000 -92.74%
Jul 03, 2023 Jérôme GAZAL   62.0000 Nov 30, 2023 @ 4.1000 +93.39%
Jul 03, 2023 Jean Marc Choplin   63.1000 Nov 30, 2023 @ 4.1000 +93.50%
Jul 03, 2023 michel paurisse   62.2000 Nov 30, 2023 @ 4.1000 -93.41%
Jun 30, 2023 Laurent Desmulliez   68.4000 Nov 30, 2023 @ 4.1000 -94.01%
Jun 29, 2023 Jean Marck Gillet   80.0000 Nov 30, 2023 @ 4.1000 -94.88%
Jun 22, 2023 Alex Ghenea   83.5000 Nov 30, 2023 @ 4.1000 -95.09%
Jun 02, 2023 Claire Havet   92.6000 Nov 30, 2023 @ 4.1000 +95.57%
May 19, 2023 Mathieu Bigois   91.0000 Nov 30, 2023 @ 4.1000 +95.49%
May 19, 2023 Laurent Gallet   93.7000 Nov 30, 2023 @ 4.1000 -95.62%
May 18, 2023 Gretta Garbo   96.2000 Sep 29, 2023 @ 4.7950 -95.02%
May 15, 2023 Ernesto Pailos   98.4000 Oct 19, 2023 @ 4.6500 -95.27%
May 12, 2023 said assade kassim   104.2000 Nov 30, 2023 @ 4.1000 -96.07%
May 10, 2023 Christian VALLER   107.4000 Nov 30, 2023 @ 4.1000 -96.18%
May 10, 2023 thiago alm   1.0260 Sep 07, 2023 @ 0.4200 -59.06%
May 09, 2023 Sébastien Dion   112.4000 Nov 30, 2023 @ 4.1000 +96.35%
Apr 28, 2023 JP Faust   78.3000 Nov 30, 2023 @ 4.1000 +94.76%
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

PHXM Comments

Write your thoughts about Phaxiam Therapeutics SA
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Michael Corrao
Michael Corrao Sep 04, 2021 8:35PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
WEBINAR ON ERYASPASE IN PANCREATIC CANCER (SEPTEMBER 1, 2021)ERYTECH TO PARTICIPATE IN THE CITI 16TH ANNUAL BIOPHARMA CONFERENCE(September 8 2021 through September 10, 2021)ERYTECH HOSTING KEY OPINION LEADER WEBINAR ON ERYASPASE IN PANCREATIC CANCERERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer(September 1 2021)ERYTECH GRANTED U.S. FDA FAST TRACK DESIGNATION FOR ERYASPASE IN HYPERSENSITIVE ALL(July 29, 2021)Erytech is starting the push for sales, fda approval by the end of the month if not sooner. After fda approval eryteck will hit the ceiling.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email